Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA

NCT05650333 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05650333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05650333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL PK, PD, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE PK AND PD OF MULTIPLE-DOSE RITLECITINIB IN CHILDREN 6 TO LESS THAN 12 YEARS OF AGE WITH SEVERE ALOPECIA AREATA
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
March 2, 2023
Completion date
August 11, 2023
Enrollment
15 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata